Resolve Digital Health Inc., a cutting edge Canadian developer of Medical Cannabis delivery systems and devices, has formed a joint venture with LeafCann Group, a leader in the production and development of cannabis medications, clinical research and education, based in Melbourne, Australia. This initiative will grant LeafCann Group a license to register and promote Resolve Digital Health’s proprietary Breeze Inhaler system in the Australian market. In addition, LeafCann Group and Resolve Digital Health will conduct clinical trials and pilot studies on the device and formulations in Australia.
LeafCann Group will retain an exclusive license to sell and distribute the Breeze device for 3 years, with an option to extend. LeafCann Group will seek import licenses for the Breeze Inhaler and pods for clinical trials and to meet demand from Australia’s Special Access Schemes, which allow for limited access to medical devices not yet registered on the Australian Register of Therapeutic Goods.
Speaking about this new collaboration, Robert Adelson, CEO of Resolve Digital Health Inc., stated, “Whether in Canada or Australia, our number one priority is patient care. Resolve Digital Health is pleased to be working with LeafCann to bring relief to Australians who have been prescribed Medical Cannabis in treatment of their ailment.”
The burgeoning global Medical Cannabis industry is estimated to reach $50 billion by 2025. In support of the growth of the industry in both Australia and Canada, LeafCann and Resolve will collaborate on a series of clinical trials that focus upon symptom relief. Around the world, Medical Cannabis is prescribed for a plethora of medical conditions, including chronic pain, arthritis and joint disease, migraine headaches, cancer/chemotherapy, fibromyalgia, MS, and many more.
“This agreement provides high quality Medical Cannabis products and devices to the Australian market, to meet the needs of patients at end of life and those permitted to access Medical Cannabis products under Australia’s Special Access Schemes,” said LeafCann Group CEO, Dr. Jaroslav Boublik B.Sc.(Hons) Ph.D. (Med), MRACI, C.Chem. AACNEM, MICRS.
About Resolve Digital Health
Resolve Digital Health is positioned to be the leading provider of standardized Medical Cannabis for patients suffering from cancer, arthritis, migraine headaches, chronic pain and other diseases. The company’s proprietary technology and cloud-based health information platform found in Resolve’s debut product Breeze addresses the numerous issues with currently available methods of cannabis delivery – establishing a standard of care and rigorous medical approach previously missing from the Medical Cannabis industry. With over two years of research and development, the complete product ecosystem will be initially available Fall 2017 in select dispensaries. For more information, visit resolvedigitalhealth.com
LeafCann Group Pty Ltd. is a leading Australian producer and developer of clinical research, product development, education and industry advice to a range of Australian and international partners. LeafCann Group has positioned itself as Australia’s preeminent Medical Cannabis think tank. With strong strategic partnerships, a diverse team and significant investment in Medical Cannabis production in Australia, LeafCann Group is well positioned as a global leader. For more information, visit leafcann.com.au
Source: 420Intel – Medical Cannabis